Bleil Lynn Dorsey 4

What Happened Lynn Dorsey Bleil, a director of Amicus Therapeutics (FOLD), disposed of 113,941 common shares on 2026-04-27 for $14.50 per share, generating $1,652,145. The filing also shows multiple derivative dispositions on the same date (options and restricted stock units) in connection with the company’s acquisition by BioMarin Pharmaceutical Inc. The stock and derivative actions were merger-related disposals to the issuer rather than open-market sales.

Key Details

• Transaction date: 2026-04-27.
• Cash sale: 113,941 shares at $14.50 each = $1,652,145.
• Additional items: 75,736 restricted stock units vested and were disposed and 38,205 common shares were included in the cashable consideration (together matching the 113,941 shares above per footnote).
• Options: Each reported stock option was fully vested and cancelled in the merger and converted into the right to receive a cash payment equal to (per-share merger price of $14.50 minus the exercise price) × number of option shares. The filing lists several derivative dispositions with amounts marked N/A; the option cash amounts are not individually disclosed in the Form 4.
• Filing timeliness and post-transaction beneficial ownership: the filing does not specify a late filing flag or the insider’s remaining shareholdings after these transactions.

Context These disposals were consummated as part of the acquisition of Amicus by BioMarin and reflect deal consideration (cash-out of shares, vested RSUs, and cancellation/settlement of options). Merger-related dispositions are transactional in nature (procedural cash settlements) rather than routine open-market insider sales; they do not by themselves indicate the insider’s ongoing view of the company’s prospects.